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peutic target, because its clinical consequence is equally fatal as 
a major complication of ICH1,9,13,15). It occurs most frequently 
within three hours of symptom onset2,4,9,13), but also at delayed 
phases7,12). 
The well-known radiological marker “spot sign” on the com-
puted tomography brain angiography (CTA) images has been 
introduced to be an independent predictor of hematoma expan-
sion in many studies14,17,24,26,32). The neuroendovascular patho-
physiology of spot sign is not yet fully understood, however, it is 
widely speculated to contribute to the chronologically heteroge-
neous nature of hematoma formation8,19,29). This time-depen-
dent feature could further explain an evolving spectrum of spot 
signs which are observed dynamically at different timelines of 
hematoma expansion12,16). The fact that not all spot sign positive 
INTRODUCTION
Spontaneous intracerebral hemorrhage (ICH) is one of the 
most detrimental stroke types worldwide, leading to an adverse 
neurological sequelae and high rates of one month mortality of 
30–50%27,31). The time-dependent nature of ICH requires early 
diagnosis and prompt decision for rapid management to pre-
vent further progression of the disease20,25,28). Despite the efforts 
of many on-going clinical trials to fight ICH, survivors of ICH 
with good outcome comprise only 30% approximately10) and no 
proven therapy is yet established to improve the survival rates 
and functional outcome due to the irreversible damage of brain 
parenchyma by the hematoma itself and its growth4,9,13,20). In-
hospital hematoma expansion is a potentially modifiable thera-
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Objective : The spot sign is related with the risk of hematoma expansion in spontaneous intracerebral hemorrhage (ICH). However, not all spot sign 
positive patients undergo hematoma expansion. Thus, the present study investigates the specific factors enhancing the spot sign positivity in predict-
ing hematoma expansion.
Methods : We retrospectively studied 316 consecutive patients who presented between March 2009 to March 2011 with primary ICH and whose ini-
tial computed tomography brain angiography (CTA) was performed at our Emergency Department. Of these patients, 47 primary ICH patients present-
ed spot signs in their CTA. We classified these 47 patients into two groups based on the presence of hematoma expansion then analyzed them with 
the following factors : gender, age, initial systolic blood pressure, history of anti-platelet therapy, volume and location of hematoma, time interval from 
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Results : Of the 47 spot sign positive patients, hematoma expansion occurred in 26 patients (55.3%) while the remaining 21 (44.7%) showed no ex-
pansion. The time intervals from symptom onset to initial CTA were 2.42±1.24 hours and 3.69±2.57 hours for expansion and no expansion, respec-
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patients developed hematoma expansion raises the question of 
the emphasizing factors associated with the prevalence of he-
matoma expansion specifically in the spot sign positive patients 
at the hyperacute phase of ICH.
MATERIALS AND METHODS
Patients and clinical parameters
We retrospectively studied 358 patients with ICH who visited 
our institution between March 2009 and March 2011. Our in-
stitution has a primary protocol of performing a routine CTA 
with contrast in all non-traumatic ICH patients. However, there 
were cases in which we were unable to perform CTA on arrival 
due to the following situations : 1) 23 patients had kidney dys-
function; 2) five patients underwent CT scans with contrast to 
evaluate other parts of the body within 24 hours; 3) nine patients 
underwent brain CT with contrast from other hospitals within 
24 hours; and 4) five patients underwent a non-contrast CT 
(NCCT), because they did not consent to brain CT with contrast 
on arrival. The remaining 316 patients underwent initial CTA 
without any conflict.
All spot sign positive patients underwent a follow-up NCCT 
within 24 hours. The follow-up NCCT of spot sign negative pa-
tients took place when there were newly developed neurologic 
symptoms within 24 hours. The exclusion criteria of this study 
included patients with ICH originated from aneurysmal rup-
ture, vascular malformation, neoplasm, dissection, hemorrhagic 
transformation of acute ischemic stroke, 
and trauma. We classified 47 spot sign 
positive patients into two subgroups 
based on the presence of hematoma ex-
pansion in the follow-up NCCT. Data 
for each group was analyzed considering 
gender, age, initial systolic blood pres-
sure, history of anti-platelet therapy, vol-
ume and location of hematoma, time 
interval from symptom onset to initial 
CTA, spot sign number, axial dimension 
and Hounsfield Unit (HU) of spot signs.
Hematoma expansion was defined by 
an increase in volume of >33% or >6 mL 
from the baseline brain CT scan by the 
criteria of Wada et al.32). The spot sign was 
identified as one or more 1–2 mm foci of 
enhancement within the hematoma on 
CTA source images32). Hematoma vol-
ume measurement was validated using 
the ABC/2 method21). The axial dimen-
sion of spot sign was defined as the lon-
gest diameter of a spot within the hema-
toma. The spot signs were independently 
verified and confirmed by one neurora-
diologist and two neurovascular surgeons 
from our institution.
Imaging studies
All brain CT scans were performed according to the standard 
departmental protocols on 64-channel CT scanners (Philips, 
Brilliance CT-64 channel scanner, Eindhoven, The Nether-
lands). Pre-contrast image examinations were performed using 
brain standard technique with 120 kVp, 150 mA, and 5-mm 
slice thickness reconstruction prior to CTA. CTA was subse-
quently performed by scanning from the C1 vertebral body to the 
parietal vertex using axial technique with the following param-
eters : 0.891 pitch; 64×0.625 mm collimation; 280 mA; 120 kVp; 
30 cm field of view; table speed 16 mm/rotation; gantry rotation 
speed 0.5 s/rotation; reconstructed section thickness 0.5 mm; 
reconstruction increment 0.3 mm; Iohexol (Bonorex 350; Dai-
han Pharm, Seoul, Korea) 300 mgI/mL (administered by power 
injector at 4.5 mL per second); and a fixed 10-second delay be-
tween the onset of contrast injection and the start of scanning. 
The contrast varies (80–100 mL) depending on the age, weight, 
and cardiac output of the patient.
Statistical analysis
All parameters were evaluated retrospectively. Prognostic 
factors were evaluated with a chi-square test, Student t-test, re-
ceiver operation characteristic (ROC) curve, and binary logistic 
regression test with significance defined as p<0.05. All statistical 
analysis was performed with commercial software (Predictable 
A B C
D E F
Fig. 1. CT angiograms of two spot sign positive patients with and without hematoma expansion. 
Brain CT scans demonstrate basal ganglia hemorrhage. The upper row CT images of a 47-year-old 
female display hematoma expansion 2 hours after presentation with a spot sign of 3.63 mm and a 
density of 194 Hounsfield units (HU) (A, B, and C). The lower row CT images of a 61-year-old male 
show no hematoma expansion 24 hours after presentation with a spot sign of 1.21 mm and a den-
sity of 117 HU (D, E, and F).
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Analysis Software, Version 18.0, IBM 
Inc., Chicago, IL, USA).
RESULTS
Study inclusion criteria resulted in 
316 consecutive patients for the study. 
Forty-seven patients (14.9%) were spot 
sign positive. Of these, 26 patients 
(55.3%) developed hematoma expan-
sion within the 24 hours follow-up CT 
scan, while the other 21 patients (44.7%) 
showed no interval change (Fig. 1). As a 
part of reference, of 269 spot sign nega-
tive patients, 31 patients (11.2%) devel-
oped hematoma expansion (data not in 
the Table). The mean volume of expand-
ed hematoma was 29.20±18.50 mL while 
the maximal and minimal volumes were 
80.00 mL and 10.00 mL, respectively, in 
the spot sign negative patients.
There was no statistical significance 
with the gender, age, initial hematoma 
volume, initial systolic blood pressure 
(SBP) and the history of anti-platelet ther-
apy in predicting hematoma expansion 
in spot sign positive patients (p>0.05 for 
all)(Table 1). Additionally, the location 
of ICH and the number of spot signs were 
statistically insignificant.
In univariate analysis, shorter time in-
terval to initial CTA (p=0.031), higher 
HU (p=0.001) and larger axial dimen-
sion of spot signs (p=0.009) were mark-
edly associated with hematoma expan-
sion. When binary logistic regression 
test was performed, shorter time interval to initial CTA and HU 
of a spot sign showed statistical significance (OR of 0.197; 95% 
CI, 0.064–0.611; and OR of 1.048; 95% CI, 1.007–1.091, respec-
tively) (Table 2). Additionally, the association between HU of a 
spot sign and hematoma expansion was investigated. When the 
cut-off value of HU was set at 171 in the ROC curve measure-
ments, the sensitivity and specificity for hematoma expansion 
were 65.4% and 85.7%, respectively (Fig. 2). The sensitivity of 
data was 100% when the absolute HU was over 191.0.
DISCUSSION
This original investigation has focused on verifying the empha-
sizing factors with prognostic significance for hematoma ex-
pansion in the spot sign positive patients. This is a single-institu-
tional study and all patients with non-traumatic ICH uniformly 
underwent CTA protocols to minimize variations in the mea-
Table 1. Clinical characteristics of hematoma expansion in spot sign positive patients
Parameters
Hematoma expansion
p value
No (n=21) Yes (n=26)
Age (years) 62.14±12.43 61.88±11.45 0.941
Gender (M : F) 11 : 10 16 : 10 0.528
Initial SBP (mm Hg) 162.33±40.720 174.22±31.890 0.500
History of anti-platelet therapy 28.6% (6/21) 38.5% (10/26) 0.345
Hematoma location 0.342
Basal ganglia 07 14
Thalamus 10 06
Lobar 03 05
Pons 01 01
Hematoma size (mL) 27.81±17.99 43.76±35.06 0.051
Time interval (hours) 3.69±2.57 2.42±1.24 0.031*
Number of spot signs 1 (n=17) 1 (n=16) 0.205
≥2 (n=4) ≥2 (n=10)
HU of a spot sign 151.10±25.140 192.12±45.970 0.001*
Axial dimension of a spot sign (mm) 02.09±1.157 4.19±3.624 0.009*
*Statistical significance based on Student t-test and chi-square test (p<0.05). M : male, F : female, SBP : sys-
tolic blood pressure, HU : Hounsfield unit, n : number of patients 
Table 2. Multivariate analysis for factors associated with hematoma expansion in patients with spot 
signs
 OR 95% CI p value
Age (years) 1.035 0.972–1.171 0.174
Gender (M : F) 0.154 0.009–1.186 0.068
Initial SBP (mm Hg) 0.998 0.943–1.051 0.873
History of anti-platelet therapy 11.02 0.006–1.489 0.093
Hematoma location 1.671 0.701–3.984 0.247
Hematoma size (mL) 0.999 0.949–1.051 0.973
No. of spot signs 0.953 0.276–3.920 0.455
Time interval (hours) 0.197 0.064–0.611 0.005*
HU of a spot sign 1.048 1.007–1.091 0.021*
Axial dimension of a spot sign (mm) 1.272 0.694–2.331 0.437
*Statistical significance based on binary logistic regression analysis for the variables associated with hematoma 
expansion and spot signs (p<0.05). OR : odds ratio, CI : confidence interval, M : male, F : female, SBP : systolic 
blood pressure, HU : Hounsfield unit
Fig. 2. Receiver operating characteristic (ROC) curve using the Hounsfield 
unit (HU). The cut-off HU value was 171 [sensitivity, 65.4%; specificity, 
85.7%; area under the ROC curve (AUC)=0.7919]. If the cut-off HU value 
was set higher than 191.0, sensitivity was 100%.
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surements of spot sign positivity and axial size. 
Unlike the multicenter studies on spot sign characteristics14,22), 
our results demonstrated that the number of spot sign was sta-
tistically insignificant in predicting hematoma expansion 
among the spot sign positive patients. The multivariate analysis 
also showed that shorter interval time from symptom onset to ini-
tial CTA and higher absolute HU of a spot sign were the specific 
factors most predictive of hematoma expansion in the spot sign 
positive patients. Huynh et al.22) addressed the issue of variations 
in measuring the spot density and size with NCCT. The same 
authors also mentioned the impracticality of risk-stratifying he-
matoma expansion by using the association of density and size 
in an acute and multicenter setting. In contrast, when our data 
was based on all patients who underwent a routine CTA, we ex-
perienced no difficulties in measuring the spot sign density and 
size effectively under an acute clinical situation. Furthermore, 
we believe that the information from our study is significantly im-
portant and easily applicable in assessing the spot sign positivity 
in higher risk groups.
Many studies reported that the factor of shorter interval time 
from symptom onset to initial CT is closely related with the risk 
of hematoma expansion, and this is firmly supported by our 
data3,4). This result strongly implicates the importance of captur-
ing or, if not possible, narrowing the range of average critical time 
of pending hematoma expansion when the spot sign was forming 
real-time. Higher HU of a spot sign may reflect an active bleeding 
site of acute ICH (i.e., the focus of impending hematoma ex-
pansion at hyperacute phase). Pathophysiologically, the question 
remains as to whether this feature indicates the site of vessel in-
juries with an on-going process of hemorrhage or the final “clot” 
of injured vessels8,29). Similarly speaking, larger axial dimension 
of a spot sign may also indicate the growing patterns of bleed-
ing site, implicating the hematoma expansion subsequently. 
The interpretations of the factors mentioned so far add to un-
derstanding the acute progressive nature of hematoma expan-
sion itself in spot sign positive patients with hyperacute ICH spe-
cifically. It is obvious that the prediction tool for hematoma 
expansion needs to be readily applicable because ICH, by its 
nature, is an abrupt clinical disease with a rapid progressive ag-
gravation jeopardizing a patient’s clinical outcome27). Realistical-
ly, one cannot wait for a follow-up brain CT to confirm hema-
toma expansion, as there is always a subgroup of ICH patients 
undergoing clinical deterioration at any time. The information 
given by the initial CTA and by stratifying patients with higher 
risks of hematoma expansion is critical in acute management of 
ICH. With this in mind, our study has demonstrated the empha-
sizing factors most predictive of hematoma expansion in spot sign 
positive patients. 
Unfortunately, at present, the positive predictive values of spot 
signs are variable between different studies depending on how 
each clinical center defines spot sign and hematoma expan-
sion9,15,24,32). For example, of 47 spot sign positive patients with 
ICH at hyperacute phase, only 55.3% developed hematoma ex-
pansion in our study. This data only represents an analysis of one 
subset of patients presented “ultra-early” to our emergency de-
partment. Not all spot sign positive patients within this subset 
underwent hematoma expansion. This may also imply that the 
simple presence of spot sign itself is insufficient to predict hema-
toma expansion. For the past few years, many efforts have been 
made to characterize spot signs for better detection through de-
signing useful spot sign scoring systems6,23) and through the expe-
riences with various CT modalities for real-time information of 
spot signs30). This has helped the clinicians in developing a bet-
ter understanding of the link between hematoma expansion and 
spot signs. Nevertheless, the optimal time for spot sign detection 
for better prediction of hematoma expansion may not be possi-
ble as a spot sign is currently conceptualized to evolve during he-
matoma expansion due to its dynamic pathophysiological na-
ture16,30). For this reason, we sought to investigate the factors that 
strongly emphasize the spot sign positivity for better prediction 
of hematoma expansion at hyperacute phase of ICH specifically.
There are limitations in this study. This investigation does 
not intend to analyze the spot sign positive patients with hema-
toma expansion at the delayed phase of ICH. Further studies 
are required, firstly, to classify a wider range of subsets of patients 
at different timelines of ICH. Secondly, the analysis of each sub-
set will help define a common feature of factors most predictive 
of hematoma expansion for the whole spot sign positive popu-
lation at different times. There needs to be a separate investiga-
tion for a substantial group of hematoma expansion with spot 
sign negative patients to help understanding the pathology of 
spot signs17). It is equally important to note that 11.2% (31/269) of 
spot sign negative patients underwent hematoma expansion. This 
suggests the dynamic nature of spot sign in the time sequence of 
ICH development where spot signs may evolve and disappear 
at certain time from ictus as being the hemostatically unstable 
lesions of ICH. Further studies will be required to seek the elusive 
time line to link the spot sign formation and hematoma expan-
sion, which will guide the neurosurgeons to make decisions for 
planning treatment. This study also needs to consider the fact 
that ICH is medically complex as patients usually are presented 
with premorbid conditions of putative risk factors33). The recent 
publications on the genetic5) and biochemical serum markers11) 
concerning ICH and hematoma expansion are other areas to be 
investigated in terms of the role of spot sign. These may help en-
hancing the predictive power of spot sign positivity in hematoma 
expansion as it is reasonable to say that they all eventually influ-
ence the pathology of forming spot signs. Gazzola et al.18) report-
ed the vascular and nonvascular mimics of the CTA spot signs, 
and these present another limitations to consider when inter-
preting our data. Lastly, there may be inter-observer and intra-
observer variability which could act as a confounding factor in 
analyzing spot signs.
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CONCLUSION
As many studies have already explored the potential of spot 
signs in predicting hematoma expansion, we have further ana-
lyzed the factors that concurrently emphasized the spot sign 
positivity in predicting hematoma expansion with patients pre-
senting with ICH at hyperacute phase. From this study, spot sign 
positivity is predictive of hematoma expansion under the con-
ditions of shorter time from symptom to initial CTA and higher 
HU of spot signs. It will be our next task to unravel the common 
features of both spot sign positive and negative patients with 
hematoma expansion in order to investigate the strategic charac-
terization and treatment of the high-risk ICH population.
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